GSK‐3β has been strongly implicated in the processes of learning and memory (Hernandez, Borrell, Guaza, Avila, & Lucas, 2002; Hooper et al., 2007) as well as in neuroprotection (Leeds et al., 2014), and its inhibition could be a central contributor to DFO's impact in neurologic disease and injury. This evidence concerns the gene GSK3B and nervous system disorder.